Considerations for widespread implementation of blood‐based biomarkers of Alzheimer's disease
Diagnosing Alzheimer's disease (AD) poses significant challenges to health care, often resulting in delayed or inadequate patient care. The clinical integration of blood-based biomarkers (BBMs) for AD holds promise in enabling early detection of pathology and timely intervention. However, several critical considerations, such as the lack of consistent guidelines for assessing cognition, limited understanding of BBM test characteristics, insufficient evidence on BBM performance across diverse populations, and the ethical management of test results, must be addressed for widespread clinical implementation of BBMs in the United States. The Global CEO Initiative on Alzheimer's Disease BBM Workgroup convened to address these challenges and provide recommendations that underscore the importance of evidence-based guidelines, improved training for health-care professionals, patient empowerment through informed decision making, and the necessity of community-based studies to understand BBM performance in real-world populations. Multi-stakeholder engagement is essential to implement these recommendations and ensure credible guidance and education are accessible to all stakeholders.
Authors
- Lawren VandeVrede (ORCID: https://orcid.org/0000-0002-8304-6711)
- Yan Hu (ORCID: https://orcid.org/0000-0003-3269-4505)
- Mark Monane (ORCID: https://orcid.org/0000-0003-1550-4415)
- Fabricio Ferreira de Oliveira (ORCID: https://orcid.org/0000-0002-8311-0859)
- Richard Batrla
- Katherine A. Partrick
- Soeren Mattke (ORCID: https://orcid.org/0000-0003-4666-9132)
- Chinedu Udeh‐Momoh (ORCID: https://orcid.org/0000-0002-7357-4692)
- Ara S. Khachaturian (ORCID: https://orcid.org/0000-0001-9973-5039)
- Joel B. Braunstein (ORCID: https://orcid.org/0000-0002-1155-0206)
- Oskar Hansson (ORCID: https://orcid.org/0000-0001-8467-7286)
- Eli Shobin (ORCID: https://orcid.org/0000-0001-7172-1065)
- Jamie Tyrone
- Pei‐Jung Lin (ORCID: https://orcid.org/0000-0001-6707-4619)
- J. Wesson Ashford (ORCID: https://orcid.org/0000-0001-9600-6471)
- Andreas Jeromin
- Sasha Bozeat
- Drew Holzapfel
- Daryl Jones
- George Vradenburg
- Suzanne E. Schindler (ORCID: https://orcid.org/0000-0002-1680-1465)
- Samantha C. Burnham (ORCID: https://orcid.org/0000-0003-4805-5193)
- Marwan N. Sabbagh (ORCID: https://orcid.org/0000-0001-8139-3309)
- John Dwyer
- Michelle M. Mielke (ORCID: https://orcid.org/0000-0001-7177-1185)
- Matthew Anderson
- Deanna Willis (ORCID: https://orcid.org/0000-0003-2760-2936)
- James F. Murray
- Emily Scholler (ORCID: https://orcid.org/0009-0000-5811-034X)
- Zul Merali (ORCID: https://orcid.org/0000-0002-6360-7913)
- Michael W. Weiner
- Dylan Young
- Allyson Rosen (ORCID: https://orcid.org/0000-0003-2222-7882)
- Joan Weiss
Institutions
- University of Southern California (US)
- Roche (Switzerland) (CH)
- Tufts Medical Center (US)
- Biogen (United States) (US)
- Barrow Neurological Institute (US)
- Eli Lilly (United States) (US)
- University of California, San Francisco (US)
- Lund University (SE)
- VA Palo Alto Health Care System (US)
- Health Resources and Services Administration (US)
- Palo Alto Veterans Institute for Research (US)
- C2N Diagnostics (United States) (US)
- Atrium Medical Cente (US)
- University Memory and Aging Center (US)
- Alzheimer’s Disease Neuroimaging Initiative (US)
- Aga Khan University Nairobi (KE)
- Global Alzheimer's Platform Foundation (US)
- Prevent Alzheimer’s Disease 2020 (US)
- Skåne University Hospital (SE)
- Eisai (United States) (US)
- Patient Advocate Foundation (US)
- Indiana University School of Medicine
- Wake Forest University (US)
- Indiana University – Purdue University Indianapolis (US)
- Universidade Federal de São Paulo (BR)
- Stanford University (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2024-10-06
- DOI
- https://doi.org/10.1002/alz.14150
- Citations
- 35
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 13.50
Funders
- Eli Lilly and Company
- Eisai